Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 5/20 | 0.58 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.54 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.51 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.51 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321662 | 0.98 | THRA (0.64) | THRATHRBBCHEACHETP53 | |
| Hydrochloric Acid SCHEMBL11672602 | 0.94 | BCHE (0.58) | THRATHRBBCHEACHE | |
| Hydrochloric Acid SCHEMBL11673412 | 0.90 | HRH3 (0.60) | BCHEACHELMNACHRM2HTR1A | |
| SCHEMBL14329438 | 0.88 | THRA (0.53) | THRATHRBBCHETP53TSHR | |
| SCHEMBL5424873 | 0.88 | HRH3 (0.61) | BCHEACHELMNACHRM2HTR1A | |
| SCHEMBL162987 | 0.87 | TP53 (0.64) | TP53TSHRGAA | |
| SCHEMBL12072552 | 0.87 | THRA (0.53) | THRATHRBBCHEACHETP53 | |
| Hydrochloric Acid SCHEMBL3853408 | 0.87 | TP53 (0.69) | THRATHRBBCHEACHETP53 | |
| Hydrochloric Acid SCHEMBL15049975 | 0.87 | TP53 (0.69) | THRATHRBBCHEACHETP53 | |
| SCHEMBL434056 | 0.85 | L3MBTL1 (0.67) | THRATHRBBCHEACHETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102675267-B | Preparation method of dronedarone hydrochloride and intermediate of dronedarone hydrochloride | JINAN FUCHUANG PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | claimed |
| EP-2521720-B1 | NEW PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI SA (FR) | 2014-03-12 | — | — | EP | claimed |
| US-8658809-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2014-02-25 | — | — | US | claimed |
| US-20120330036-A1 | Process for the preparation of dronedarone | SANOFI (FR) | 2012-12-27 | — | — | US | claimed |
| EP-2521720-A1 | NEW PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2012-11-14 | — | — | EP | claimed |
| WO-2011083346-A1 | NEW PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2011-07-14 | — | — | WO | claimed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | claimed |
| CN-1295200-C | 2-butyl-3- (4- [3- (dibutylamino) propoxy ] benzoyl) -5-nitrobenzofuran hydrochloride and preparation thereof | SANOFI SYNTHELABO (FR) | 2007-01-17 | — | — | CN | claimed |
| EP-1351907-B1 | 2-BUTYL-3-(4- 3(DIBUTYLAMINO)PROPOXY BENZOYL)-5-NITRO-BENZOFURAN HYDROCHLORIDE AND PREPARATION THEREOF | SANOFI AVENTIS (FR) | 2006-11-15 | — | — | EP | claimed |
| CN-1229366-C | Methanesulphonamido-benzofuran derivatives, process for their preparation and their use as synthesis intermediates | SANOFI SYNTHELABO (FR) | 2005-11-30 | — | — | CN | claimed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | claimed |
| US-6846936-B2 | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof | SANOFI-SYNTHELABO (FR) | 2005-01-25 | — | — | US | claimed |
| US-6828448-B2 | 2-butyl-5-(methanesulfonamido)benzofuran; preparation of dronedarone | SANOFI-SYNTHELABO (FR) | 2004-12-07 | — | — | US | claimed |
| EP-1343777-B1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI SYNTHELABO (FR) | 2004-05-06 | — | — | EP | claimed |
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | SANOFI (FR) | 2004-03-11 | — | — | US | claimed |
| CN-1479735-A | Methanesulphonamido-benzofuran derivative, preparation method and use thereof as synthesis ntermediate | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-03-03 | — | — | CN | claimed |
| US-20040010032-A1 | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof | SANOFI (FR) | 2004-01-15 | — | — | US | claimed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | claimed |
| CN-102675267-B | Preparation method of dronedarone hydrochloride and intermediate of dronedarone hydrochloride | JINAN FUCHUANG PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330036-A1 | Process for the preparation of dronedarone | CYP2D6, CYP3A4, CYP2B6 | BCHE 1048/4885ACHE 2008/4885CHRM2 2142/4885 |
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | CYP2F1, DHPS, CYP2D6 | BCHE 1500/4885ACHE 2724/4885CHRM2 4658/4885 |
| US-20050049302-A1 | Process for the preparation of dronedarone | CACNA1C, CACNA1A, KCNH1 | BCHE 922/4885ACHE 355/4885CHRM2 2333/4885 |
| US-20040010032-A1 | 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof | CYP2D6, DBF4, DUT | BCHE 1447/4885ACHE 2352/4885CHRM2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.